Lipidated GLP-1 Analogs Protease Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing long-acting peptide therapeutics are hindered by short plasma half-life and poor oral bioavailability due to enzymatic degradation, which is challenging to address without causing metabolic disturbances.
Innovation Solution
The development of lipidated peptides with specific amino acid modifications, such as lipidation of lysine residues with PEG or palmitoyl moieties, to enhance protease resistance while maintaining receptor potency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide therapeutics are administered to achieve therapeutic effect, then receptor potency is improved, but plasma half-life is shortened due to enzymatic degradation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of amino acid residues within the peptide sequence. Specifically, it incorporates unnatural amino acids with modified side chains (e.g., cyclopropylalanine, aminoisobutyric acid) and performs lipidation at defined positions to alter the peptide's physicochemical properties. These structural parameter changes confer resistance to proteolytic enzymes while preserving receptor binding affinity, thereby extending plasma half-life without sacrificing therapeutic potency.
Solution Approach 2:
The patent creates composite structures by combining natural amino acid residues with unnatural amino acid surrogates within the peptide backbone. The incorporation of lipid-modified amino acids (e.g., palmitoyl-cysteine) creates a composite molecule that integrates both the bioactive peptide portion and the protease-resistant lipidated portion, achieving simultaneous receptor potency and enzymatic stability.
2Stability of the object's composition
If protease resistance is increased through sequence modifications, then enzymatic stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the peptide modification strategy into discrete, modular components: specific amino acid positions are selected for modification (positions 8, 15, 20, 26, 30), each with defined modification types. This segmented approach to structural modification allows for systematic synthesis and quality control, reducing manufacturing complexity compared to global random modifications.
Solution Approach 2:
The patent implements local quality by applying modifications only at specific strategic positions within the peptide sequence rather than throughout the entire structure. Lipidation is performed at defined residues (e.g., Lysine at position 26), and unnatural amino acids are incorporated at specific locations. This localized modification approach maintains manufacturing feasibility while achieving the desired enzymatic stability.
3Reliability
If peptide structure is modified to resist degradation, then protease resistance is improved, but oral bioavailability deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying the peptide's amphipathic character through lipidation and incorporation of hydrophobic unnatural amino acids. These parameter changes in hydrophobicity and membrane permeability properties enable the peptide to withstand gastric conditions and facilitate intestinal absorption, thereby improving oral bioavailability while maintaining protease resistance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipidated peptides demonstrate increased stability against proteolytic degradation, maintaining or enhancing receptor potency and selectivity, and can be administered orally, improving the therapeutic potential of peptide-based treatments.
Implementation Method 1
The lipidated peptides demonstrate increased stability against proteolytic degradation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substituition of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.